I assume your estimation "that ABBV’s 3-DAA regimen will garner about 100K of the available 260K patients per year in the US and EU, a market share of 38%" refers to a scenario in which both regimens from GILD and ABBV require 12 weeks treatment duration and both contain ribavirin (I think it is pretty sure both regimens have similar SVR rates in this case).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.